Received Apr 8, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | — | IM |
Fever; Injection site pain; Injection site itching; Injection site erythema; injection site warm; injection site sensitivity to touch; This non-serious case was reported by a consumer via call center representative and described the occurrence of fever in a 65-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis. On 30-MAR-2026, the patient received the 1st dose of Shingrix (intramuscular, unknown deltoid). On 30-MAR-2026, less than a day after receiving Shingrix, the patient experienced fever (Verbatim: Fever), injection site pain (Verbatim: Injection site pain), injection site itching (Verbatim: Injection site itching), injection site erythema (Verbatim: Injection site erythema), injection site warmth (Verbatim: injection site warm) and injection site hypersensitivity (Verbatim: injection site sensitivity to touch). On 01-APR-2026, the outcome of the fever was resolved (duration 2 days). The outcome of the injection site pain and injection site itching were resolving and the outcome of the injection site erythema, injection site warmth and injection site hypersensitivity were not resolved. It was unknown if the reporter considered the fever, injection site pain, injection site itching, injection site erythema, injection site warmth and injection site hypersensitivity to be related to Shingrix. It was unknown if the company considered the fever, injection site pain, injection site itching, injection site erythema, injection site warmth and injection site hypersensitivity to be related to Shingrix. Additional Information: GSK Receipt Date: 02-APR-2026 The patient self-reported this case. The reporter mentioned that the beginning of that evening the patient began experiencing fever which had subsided, achiness and itching, which are slowly subsiding, and warmth, sensitivity to touch and redness extending to about 2 inches below the injection site, which was ongoing. The batch number was not provided upon follow- up with the reporter.